ReviewPhysics and imaging in radiation oncology2025
Diffusion-weighted imaging-derived parameters as quantitative imaging biomarkers in magnetic resonance-guided radiotherapy: a systematic review.
Review in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maintaining quality of scientific peer-review and publishing inPhysics and imaging in radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Magnetic Resonance Linear Accelerators (MR-LINACs) have transformed radiotherapy by integrating high-resolution magnetic resonance imaging (MRI) with precise radiation delivery. Diffusion-Weighted Imaging (DWI)-derived parameters are promising non-invasive quantitative imaging biomarkers (QIBs) for MR-guided radiotherapy (MRgRT), primarily through apparent diffusion coefficient (ADC) and intravoxel incoherent motion (IVIM) models; however, their clinical utility and validation on MR-LINAC systems remain underexplored. This systematic review evaluates DWI's technical development, validation, and clinical role in MRgRT using MR-LINACs. Material and methods: Following PRISMA guidelines, PubMed/MEDLINE, Web of Science, and Scopus (2014-2024) were searched for English-language studies on DWI in MRgRT with MR-LINACs (0.35 T or 1.5 T). Eligible studies included technical and clinical research with phantoms, volunteers, or patients. Data on study characteristics, DWI protocols, validation metrics, and clinical endpoints were extracted and qualitatively synthesized; heterogeneity precluded Results: Thirty-four studies (11 at 0.35 T, 23 at 1.5 T) were included (29 prospective, 5 retrospective), with 28 involving patients (N = 484) across cancers. DWI, primarily via single-shot EPI (median time ∼4-5 min, b-values 0-2000 s/mm Discussion: DWI on MR-LINACs is technically available, feasible, and clinically promising for MRgRT. However, its QIB potential is limited by inconsistent protocols, hardware constraints, and preliminary clinical validation. Standardized protocols, hardware upgrades, and rigorous multi-center trials are essential to establish DWI-derived parameters as reliable QIBs for MRgRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.